Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$199 Mln
Revenue (TTM)
$77 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
3.1
Industry P/E
--
EV/EBITDA
-4.2
Div. Yield
0 %
Debt to Equity
0.6
Book Value
$1.2
EPS
$-0.7
Face value
--
Shares outstanding
54,005,984
CFO
$-247.34 Mln
EBITDA
$-266.31 Mln
Net Profit
$-279.60 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sight Sciences Inc (SGHT)
| -55.6 | -31.8 | -55.6 | 53.7 | -26.2 | -- | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Sight Sciences Inc (SGHT)
| 117.9 | -29.3 | -57.7 | -30.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Sight Sciences Inc (SGHT)
|
3.5 | 198.7 | 77.4 | -38.4 | -48.0 | -50.7 | -- | 3.1 |
| 7.9 | 5,176.8 | 6,552.2 | -530.2 | -4.1 | -9.2 | -- | 0.9 | |
| 36.8 | 5,222.6 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.1 | |
| 25.8 | 3,989.0 | 2,719.5 | 47.0 | 8.4 | 1.6 | 86.6 | 1.3 | |
| 112.8 | 6,098.9 | 507.4 | -187.7 | -36.2 | -26.4 | -- | 8.9 | |
| 76.1 | 4,758.4 | 1,541.6 | 233.6 | 21.6 | 21.4 | 21.4 | 4.5 | |
| 178.6 | 9,411.8 | 1,526.9 | -151.5 | 20.0 | -17.1 | -- | 12.9 | |
| 330.4 | 12,879.6 | 1,403.7 | 177.7 | 14.7 | 13.8 | 72.5 | 9.2 | |
| 117.8 | 6,280.4 | 738.3 | 48.9 | 11.4 | 2.4 | 129.6 | 3.0 | |
| 32.1 | 13,409.8 | 6,178.4 | 626.5 | 13.0 | 11.9 | 22.1 | 2.6 |
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two... segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California. Address: 4040 Campbell Avenue, Menlo Park, CA, United States, 94025 Read more
Co-Founder, President, CEO & Director
Mr. Paul Badawi
Co-Founder, President, CEO & Director
Mr. Paul Badawi
Headquarters
Menlo Park, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Sight Sciences Inc (SGHT) is $3.52 (NASDAQ) as of 02-Apr-2026 16:00 EDT. Sight Sciences Inc (SGHT) has given a return of -26.15% in the last 3 years.
Since, TTM earnings of Sight Sciences Inc (SGHT) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-10.73
|
6.45
|
|
2024
|
-3.53
|
2.08
|
|
2023
|
-4.55
|
2.10
|
|
2022
|
-6.80
|
3.66
|
|
2021
|
-7.53
|
2.04
|
The 52-week high and low of Sight Sciences Inc (SGHT) are Rs 9.24 and Rs 2.03 as of 03-Apr-2026.
Sight Sciences Inc (SGHT) has a market capitalisation of $ 199 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Sight Sciences Inc (SGHT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.14
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.